Paragon 28 Inc. Stock
€6.20
Your prediction
Financial data and news for Paragon 28 Inc.
sharewise wants to provide you with the best news and tools for Paragon 28 Inc., so we directly link to the best financial data sources.
Financials
News
Paragon 28 Introduces a Novel Right-Angle Drill for the APEX 3D™ Total Ankle Replacement System
Paragon 28, Inc. (NYSE: FNA) is pleased to announce the addition of a novel Right-Angle Drill to the APEX 3D™ Total Ankle Replacement System designed to improve tibia preparation prior to the
Paragon 28 Launches the R3FLEX™ Stabilization System to Anatomically Repair Ankle Syndesmotic Injuries
Paragon 28, Inc. (NYSE: FNA), is pleased to announce the launch of the R3FLEX™ Stabilization System, which is designed to restore stability to the ankle syndesmosis after injury from an ankle
Paragon 28 Adds to Suite of Novel Syndesmosis Repair Solutions with Launch of Grappler® R3INFORCE™ Extraosseous Repair System
Paragon 28, Inc. (NYSE: FNA), is pleased to announce the launch of the Grappler® R3INFORCE™ Extraosseous Repair System designed to restore stability to the anterior and posterior ligaments
Paragon 28 Appoints Chadi Chahine as Chief Financial Officer and Executive Vice-President of Supply Chain Operations, Reports Second Quarter 2024 Financial Results and Narrows 2024 Net Revenue Guidance
Paragon 28, Inc. (NYSE: FNA) (“Paragon 28” or "Company”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today announced that Chadi Chahine has been
Paragon 28 to Report Second Quarter 2024 Financial Results on August 8, 2024
Paragon 28, Inc. (NYSE: FNA) (“PARAGON”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, announced it will report financial results for the second
Paragon 28 Reports First Quarter 2024 Financial Results and Reaffirms 2024 Net Revenue Guidance
Paragon 28, Inc. (NYSE: FNA) (“Paragon 28” or "Company”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today reported financial results for the
Paragon 28 to Present at the Bank of America Securities 2024 Healthcare Conference
Paragon 28, Inc. (NYSE: FNA), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today announced that Albert DaCosta, Chairman and CEO, and Krissy Wright
Paragon 28 Announces CFO Transition, Provides Preliminary Unaudited Net Revenue for First Quarter 2024, and Reaffirms Net Revenue Guidance for Fiscal Year 2024
Paragon 28, Inc. (NYSE: FNA), (“Paragon 28” or “the Company”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today announced that Stephen Deitsch